Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0318

View: 3546 Download: 171 Web of Science: 8 Crossref: 8

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):935-938. Published online June 24, 2022

DOI: https://doi.org/10.3350/cmh.2022.0175

View: 3538 Download: 135 Web of Science: 4 Crossref: 4

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2020;26(4):461-475. Published online September 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0136

View: 8152 Download: 275 Web of Science: 34 Crossref: 37

Jeong Kee Seo

Clin Mol Hepatol. 2006;12(3):333-363. Published online January 1, 2000

View: 6801 Download: 241

1 |

Viewed By 5272	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5216	MAFLD: How is it different from NAFLD?
Viewed By 5117	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3838	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3772	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Search